The Supreme Court should be mindful of naturally derived products other than nucleic acids when deciding Myriad
The following contribution to our gene patenting symposium come from Susan McBee and Bryan Jones.
Gene Patenting Symposium
12 articles
Nothing under the sun that is made of man
The following contribution to our gene patenting symposium comes from Andrew Torrance, Professor of Law at University of Kansas School of Law. Introduction The Supreme Court may soon place its imprimatur on a principle that has been gathering force within patent law for several decades: human beings constitute unpatentable subject matter.
Questions that will remain unanswered from the Myriad case
The following contribution to our gene patenting symposium comes from Robert Cook-Deegan, Research Professor, Institute for Genome Sciences & Policy and Sanford School of Public Policy, Duke University. Association for Molecular Pathology v. Myriad Genetics is not your usual patent lawsuit.
Selected thoughts on a Myriad of problems
The following contribution to our gene patenting symposium comes from Robert Merges, Wilson Sonsini Professor of Law, UC Berkeley and Visiting Professor of Law, Stanford Law School.
Another case of certiorari improvidently granted
The following contribution to our gene-patenting symposium comes from Christopher M. Holman, Associate Professor of Law at the University of Missouri Kansas City School of Law.
An antidote to the politics of the human gene patenting debate
The following contribution to our gene patenting symposium comes from Kevin Noonan, a partner at McDonnell Boehnen Hulbert & Berghoff LLP. It is one of the misfortunes of the human gene patenting debate that there has been precious little discussion of patent law (at least from those opposing gene patents).
The practicalities of patenting a gene
The following contribution to our gene patenting symposium comes from Charles Rothfeld, Special Counsel at Mayer Brown in Washington, DC. The question in Association for Molecular Pathology v. Myriad Genetics may strike a patent lawyer very differently than it does the generalist.
A conversation between the Supreme Court & the Federal Circuit
The following contribution to our gene patenting symposium comes from Robin Feldman, Professor of Law at UC Hastings College of the Law, specializing in Intellectual Property. She has published two books, Rethinking Patent Law (Harvard 2012) and The Role of Science in Law (Oxford 2009).
The human genes case: Made simple
Later today the blog will begin publishing an online symposium on the Supreme Court case testing whether human genes, taken out of the body and isolated in a laboratory, without change, can be given a patent. A roster of the contributors to the symposium is available here.
Patentable subject matter at the Supreme Court: An exceptional case?
The following contribution to our gene patenting symposium comes from Arti K. Rai, Elvin R. Latty Professor of Law, Duke Law School and Duke Institute for Genome Sciences & Policy. From 2009-2010, Rai served as the USPTO Administrator for Policy and External Affairs.
The “runcible” product of nature doctrine
The following contribution to our gene patenting symposium comes from Dan L. Burk, Chancellor’s Professor and founding faculty member at the University of California, Irvine School of Law.
Online symposium announcement: Are genes patentable?
In early February, the blog will host an online symposium to discuss how the Court should rule (and why) on the question presented by Association for Molecular Pathology v. Myriad Genetics, Inc.: whether human genes are patentable.